Sirnaomics is a clinical stage biopharmaceutical company leveraging an outstanding level of knowledge and experience in RNA interference (RNAi) technology to forge a path to high value creation through discovery and development of therapeutics for human disorders with unmet medical needs.
TRICIDA
South San Francisco, United States · Post IPO Debt
Bizzabo
New York, United States · Series E
HoneyBook
San Francisco, United States · Series E
Plastiq
San Francisco, United States · Series E
Allurion
Wellesley, United States · Series D
Axonius
New York, United States · Series E
Providence Medical Technology
Lafayette, United States · Debt Financing
Inkling
San Francisco, United States · Series E
EarlySense
Waltham, United States · Series H
MakeSpace
New York, United States · Series E
PubNub
San Francisco, United States · Series E
Emmaus Medical
Torrance, United States · Post IPO Equity